Evidence map›Paper›PMID 39256816›Full record

ArticleStem cell research & therapy2024

Urine-derived stem cells serve as a robust platform for generating native or engineered extracellular vesicles.

Anders Toftegaard Boysen, Bradley Whitehead, Anne Louise S Revenfeld, Dhanu Gupta, Thor Petersen, Peter Nejsum

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anders Toftegaard BoysenDepartment of Clinical Medicine, Aarhus University, Aarhus N, Denmark. anderstb@clin.au.dk.ORCID 0000-0002-0192-1413
Bradley WhiteheadDepartment of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
Anne Louise S RevenfeldCenter for Gene and Cellular Therapy, Department of Clinical Immunology, Aarhus University Hospital, Aarhus N, Denmark.
Dhanu GuptaDepartment of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Thor PetersenDepartment of Regional Health Research, Southern Danish University, Sønderborg, Denmark.
Peter NejsumDepartment of Clinical Medicine, Aarhus University, Aarhus N, Denmark. pn@clin.au.dk.

Funding

Carlsbergfondet CF21-0315Danmarks Frie Forskningsfond DFF-1032-00242BJascha Fonden 2022-0357Riisfort Fonden 25/2 2022Sundhedsvidenskabelige Fakultet, Aarhus Universitet Funded PhD scholarship
6 · The paper itself

Abstract

backgroundMesenchymal stromal cell (MSC) therapy holds great potential yet efficacy and safety concerns with cell therapy persist. The beneficial effects of MSCs are often attributed to their secretome that includes extracellular vesicles (EVs). EVs carry biologically active molecules, protected by a lipid bilayer. However, several barriers hinder large-scale MSC EV production. A serum-free culturing approach is preferred for producing clinical-grade MSC-derived EVs but this can affect both yield and purity. Consequently, new strategies have been explored, including genetically engineering MSCs to alter EV compositions to enhance potency, increase circulation time or mediate targeting. However, efficient transfection of MSCs is challenging. Typical sources of MSC include adipose tissue and bone marrow, which both require invasive extraction procedures. Here, we investigate the use of urine-derived stem cells (USCs) as a non-invasive and inexhaustible source of MSCs for EV production.

methodsWe isolated, expanded, and characterized urine-derived stem cells (USCs) harvested from eight healthy donors at three different time points during the day. We evaluated the number of clones per urination, proliferation capacity and conducted flow cytometry to establish expression of surface markers. EVs were produced in chemically defined media and characterized. PEI/DNA transfection was used to genetically engineer USCs using transposon technology.

resultsThere were no differences between time points for clone number, doubling time or viability. USCs showed immunophenotypic characteristics of MSCs, such as expression of CD73, CD90 and CD105, with no difference at the assessed time points, however, male donors had reduced CD73 + cells. Expanded USCs were incubated without growth factors or serum for 72 h without a loss in viability and EVs were isolated. USCs were transfected with high efficiency and after 10 days of selection, pure engineered cell cultures were established.

conclusionsIsolation and expansion of MSCs from urine is non-invasive, robust, and without apparent sex-related differences. The sampling time point did not affect any measured markers or USC isolation potential. USCs offer an attractive production platform for EVs, both native and engineered.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsUrineAdultCell DifferentiationCell ProliferationCells, CulturedFemaleHumansMaleMiddle AgedExtracellular vesiclesMSC-engineeringNoninvasiveUrine-derived stem cells

Identifiers

PMID39256816
PMCPMC11389316

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.